Targeting myeloid cells with bispecific antibodies as novel immunotherapies of cancer

Research output: Contribution to journalReview articleAcademicpeer-review

3 Citations (Scopus)


Introduction: Most bispecific antibody (BsAb) therapies focus on stimulating the adaptive immune system, in particular T cells, to promote tumor cell killing. Another method to promote tumor eradication is through the engagement of myeloid cells, including macrophages and neutrophils, which are abundantly present and possess intrinsic cytotoxic mechanisms for tumor cell killing, making them interesting effector cells to recruit for BsAb therapy. Areas covered: In this review, we describe the evolving knowledge of the role of macrophages and neutrophils in cancer in scientific literature. Moreover, we address the BsAbs that have been developed over the years to recruit these cell types as effector cells in immunotherapy of cancer. This includes the discussion of BsAbs that target Fc receptors (i.e. FcγR and FcαRI) to induce antibody-dependent cellular phagocytosis (ADCP) by macrophages or trogoptosis via neutrophils, as well as BsAbs that interfere with checkpoint inhibition, including the SIRPα-CD47 pathway. Expert opinion: Elucidating the complexity of macrophage and neutrophil heterogeneity in cancer may help to specifically enlist the cytotoxic ability of these cells through targeting Fc receptors and checkpoint pathways, which may further enhance anti-cancer immunity.
Original languageEnglish
Pages (from-to)983–995
Number of pages13
JournalExpert Opinion on Biological Therapy
Issue number8
Early online date2022
Publication statusPublished - 19 Jul 2022


  • Bispecific antibodies
  • CD47
  • CD64
  • CD89
  • macrophages
  • myeloid cells
  • neutrophils
  • tumor

Cite this